{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:23Z","timestamp":1791475343300,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,3]]},"DOI":"10.7759\/cureus.83424","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:26:02Z","timestamp":1746307562000},"source":"Crossref","is-referenced-by-count":1,"title":["Insulin-Induced Acanthosis Nigricans"],"prefix":"10.7759","author":[{"given":"Soomal","family":"Rafique","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Dihowm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanober","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jakoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.91828","article-title":"A study of pathogenesis of acanthosis nigricans and its clinical implications","volume":"56","author":"Puri N","year":"2011","unstructured":"Puri N. A study of pathogenesis of acanthosis nigricans and its clinical implications. Indian J Dermatol. 2011, 56:678-83. 10.4103\/0019-5154.91828","journal-title":"Indian J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102519","article-title":"Acanthosis nigricans: pointer of endocrine entities","volume":"12","author":"Radu AM","year":"2022","unstructured":"Radu AM, Carsote M, Dumitrascu MC, Sandru F. Acanthosis nigricans: pointer of endocrine entities. Diagnostics (Basel). 2022, 12:10.3390\/diagnostics12102519","journal-title":"Diagnostics (Basel)"},{"key":"ref3","article-title":"Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome","volume":"15","author":"Mu\u00f1oz-P\u00e9rez MA","year":"2001","unstructured":"Mu\u00f1oz-P\u00e9rez MA, Camacho F. Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome. J Eur Acad Dermatol Venereol. 2001, 15:325-7.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.05150.x","article-title":"Genes, growth factors and acanthosis nigricans","volume":"147","author":"Torley D","year":"2002","unstructured":"Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002, 147:1096-101. 10.1046\/j.1365-2133.2002.05150.x","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.5070\/D34603S4FM","article-title":"Paraneoplastic acanthosis nigricans: the importance of exhaustive and repeated malignancy screening","volume":"16","author":"Talsania N","year":"2010","unstructured":"Talsania N, Harwood CA, Piras D, Cerio R. Paraneoplastic acanthosis nigricans: the importance of exhaustive and repeated malignancy screening. Dermatol Online J. 2010, 16:8.","journal-title":"Dermatol Online J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14794","article-title":"Drug-induced acanthosis nigricans: a systematic review and new classification","volume":"34","author":"Mourad AI","year":"2021","unstructured":"Mourad AI, Haber RM. Drug-induced acanthosis nigricans: a systematic review and new classification. Dermatol Ther. 2021, 34:e14794. 10.1111\/dth.14794","journal-title":"Dermatol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4158\/EP.10.2.101","article-title":"Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes","volume":"10","author":"Litonjua P","year":"2004","unstructured":"Litonjua P, Pi\u00f1ero-Pilo\u00f1a A, Aviles-Santa L, Raskin P. Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract. 2004, 10:101-6. 10.4158\/EP.10.2.101","journal-title":"Endocr Pract"},{"key":"ref8","article-title":"Localized acanthosis nigricans at the site of repetitive insulin injections","volume":"105","author":"Bomar L","year":"2020","unstructured":"Bomar L, Lewallen R, Jorizzo J. Localized acanthosis nigricans at the site of repetitive insulin injections. Cutis. 2020, 105:E20-2.","journal-title":"Cutis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2019.08.010","article-title":"Exogenous insulin-induced localized acanthosis nigricans: a rare injection site complication","volume":"44","author":"Pal R","year":"2020","unstructured":"Pal R, Bhattacharjee R, Chatterjee D, Bhadada SK, Bhansali A, Dutta P. Exogenous insulin-induced localized acanthosis nigricans: a rare injection site complication. Can J Diabetes. 2020, 44:219-21. 10.1016\/j.jcjd.2019.08.010","journal-title":"Can J Diabetes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac150.602","article-title":"LBSUN294 insulin-induced abdominal acanthosis nigricans from high doses of insulin U-500","volume":"6","author":"Yap SE","year":"2022","unstructured":"Yap SE, Gerges A, Oliva J, Idrees T. LBSUN294 insulin-induced abdominal acanthosis nigricans from high doses of insulin U-500. J Endocr Soc. 2022, 6:A292. 10.1210\/jendso\/bvac150.602","journal-title":"J Endocr Soc"},{"key":"ref11","article-title":"Case of exogenous insulin-derived acanthosis nigricans caused by insulin injections","volume":"39","author":"Yahagi E","year":"2014","unstructured":"Yahagi E, Mabuchi T, Nuruki H, et al.. Case of exogenous insulin-derived acanthosis nigricans caused by insulin injections. Tokai J Exp Clin Med. 2014, 39:5-9.","journal-title":"Tokai J Exp Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180705","article-title":"Acanthosis nigricans at sites of insulin injection in a man with diabetes","volume":"190","author":"Huang Y","year":"2018","unstructured":"Huang Y, Hessami-Booshehri M. Acanthosis nigricans at sites of insulin injection in a man with diabetes. CMAJ. 2018, 190:E1390. 10.1503\/cmaj.180705","journal-title":"CMAJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.07.023","article-title":"Acanthosis nigricans as a local cutaneous side effect of repeated human insulin injections","volume":"94","author":"Buz\u00e1si K","year":"2011","unstructured":"Buz\u00e1si K, S\u00e1pi Z, Jermendy G. Acanthosis nigricans as a local cutaneous side effect of repeated human insulin injections. Diabetes Res Clin Pract. 2011, 94:e34-6. 10.1016\/j.diabres.2011.07.023","journal-title":"Diabetes Res Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2007.27","article-title":"Exogenous insulin-derived acanthosis nigricans","volume":"144","author":"Mailler-Savage EA","year":"2008","unstructured":"Mailler-Savage EA, Adams BB. Exogenous insulin-derived acanthosis nigricans. Arch Dermatol. 2008, 144:126-7. 10.1001\/archdermatol.2007.27","journal-title":"Arch Dermatol"},{"key":"ref15","article-title":"Case report: acanthosis nigricans resulting from repetitive same-site insulin injections","volume":"11","author":"Brodell JD Jr","year":"2012","unstructured":"Brodell JD Jr, Cannella JD, Helms SE. Case report: acanthosis nigricans resulting from repetitive same-site insulin injections. J Drugs Dermatol. 2012, 11:e85-7.","journal-title":"J Drugs Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.5070\/D31W06W6RG","article-title":"Exogenous insulin-derived acanthosis nigricans: could it be a cause of increased insulin requirement?","volume":"19","author":"Dhingra M","year":"2013","unstructured":"Dhingra M, Garg G, Gupta M, Khurana U, Thami GP. Exogenous insulin-derived acanthosis nigricans: could it be a cause of increased insulin requirement?. Dermatol Online J. 2013, 19:9.","journal-title":"Dermatol Online J"},{"key":"ref17","article-title":"Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: findings from the EMPA-REG OUTCOME trial","volume":"23","author":"Vaduganathan M","year":"2021","unstructured":"Vaduganathan M, Inzucchi S, Sattar N, et al.. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: findings from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2021, 23:2775-84. 101111\/dom.14535","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/364864-insulin-induced-acanthosis-nigricans","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:26:03Z","timestamp":1746307563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/364864-insulin-induced-acanthosis-nigricans"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.83424","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,3]]}}}